Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$30.41 USD

30.41
18,497,848

+0.36 (1.20%)

Updated Apr 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (195 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

by Kinjel Shah

J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.

Adaptimmune (ADAP) Down on End of Collaboration With Roche

by Zacks Equity Research

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

by Zacks Equity Research

Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.

Regeneron (REGN) Accused of Fraudulent Practices Related to Eylea

by Zacks Equity Research

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

by Zacks Equity Research

ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

by Zacks Equity Research

The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

by Zacks Equity Research

Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

by Zacks Equity Research

Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.

Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data

by Zacks Equity Research

Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.

Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday

by Zacks Equity Research

Argenx (ARGX) surges after a Japanese rival posted disappointing results from a late-stage study on its investigational drug for generalized myasthenia gravis.

PTC Therapeutics (PTCT) Up on Positive Regulatory Updates

by Zacks Equity Research

PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.

Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek

by Zacks Equity Research

Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.

Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates

by Zacks Equity Research

Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

by Zacks Equity Research

Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.

Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag

by Zacks Equity Research

Halozyme's (HALO) fourth-quarter 2023 earnings meet estimates, while revenues miss the same.

Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.

Roche's (RHHBY) Xolair Gets Approval for Food Allergies

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

by Zacks Equity Research

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense

by Zacks Equity Research

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%

by Zacks Equity Research

Alnylam (ALNY) reports mixed fourth-quarter 2023 results, as earnings beat estimates, while revenues miss the same. The stock of the company falls 10%.

Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines

by Zacks Equity Research

Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.

Biogen (BIIB) Q4 Earnings & Sales Miss Estimates, Stock Falls

by Zacks Equity Research

Biogen (BIIB) misses fourth-quarter estimates for earnings and sales. Sales of Tecfidera, Tysabri & Spinraza decline.

Regeneron (REGN) Q4 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.